CA Patent

CA3051374A1 — Compositions for the treatment of hypertension

Assigned to George Institute for Global Health · Expires 2018-08-02 · 8y expired

What this patent protects

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker. These compositions are administered in a dose of 40-80% of the lowest hypertension therapeut…

USPTO Abstract

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker. These compositions are administered in a dose of 40-80% of the lowest hypertension therapeutic dose (LHTD) for each agent. The application is also directed to compositions comprising telmisartan, a thiazide-like diuretic and a calcium channel blocker, administered at a dose of 80-150% of the LHTD for each agent.

Drugs covered by this patent

Patent Metadata

Patent number
CA3051374A1
Jurisdiction
CA
Classification
—
Expires
2018-08-02
Drug substance claim
No
Drug product claim
No
Assignee
George Institute for Global Health
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.